Roche ’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness

Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each have three treatment arms, with participants randomised to receive either faricimab or aflibercept at fixed eight-week intervals, or faricimab at personalised intervals of up to 16 weeks, following a loading phase. In a secondary endpoint, across both studies, more than half of participants in the faricimab personalised dosing arms achieved an extended time between treatments of 16 weeks at year one. This is the first time any investigational medicine has achieved this level of durability in a phase III study of people with DME. Worldwide, an estimated 21 million people are living with DME, a leading cause of vision loss among working-age adults.1 Whilst anti-vascular endothelial growth factor (VEGF) monotherapy injections have significantly reduced vision loss from DME, the treatment burden associated with frequent eye injections and physician visits can lea...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsIn this study, we showed TEW-7197 and ramucirumab considerably decreased invasiveness, thus EMTness in a panel of diffuse-type GC cell lines including GC PDCs. Taken together, we confirmed that combination of TEW-7197 and ramucirumab reduced tumor spheroid and GC PDC-induced blood vessel formation concomitantly in the spheroid-on-a-chip model.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Systematically mapping the mechanical properties of skin and tissue is useful for biomechanics research and disease diagnostics. For example, later stage breast cancer and lymphoma manifest themselves as hard nodes under the skin. Currently, mechanical measurements are done manually, with a sense of touch or a handheld tool. Manual measurements do not provide quantitative information and vary depending on the skill of the practitioner. Research shows that tactile sensors could be more sensitive than a hand. We propose a method that uses our previously developed skin-crawling robots to noninvasively test the mechanical prop...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Conclusion: The proposed model is shown to adequately describe the meal-induced glucose fluctuations in simulated CGM data while validations on clinical CGM data show promising results as well. Significance: The proposed model may lay the grounds for new ways of utilizing available CGM data, including CGM-based parameter estimation and stochastic optimal control.
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
David J. BierThe Biden administrationis planning to roll out a  new policy in November that denies the right to travel or immigrate to the United States to anyone in the world who is unvaccinated. It will replace various nonsensical travel bans on Europeans, Chinese, Iranians, Brazilians, South Africans, and Indians, but a majority of the world (57 percent) has not received even a  single shot of any of the vaccines, andonly 1.9 percent of people in low ‐​income countries have received at least one dose. This includes pretty much the entire continent of Africa.Currently, everyone —vaccinated or not...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
New J. Chem., 2021, Accepted Manuscript DOI: 10.1039/D1NJ03533A, PaperLucie Melounkov á, Miriam Syková, Robert Jirásko, Roman Jambor, Radim Havelek, Eva Peterova, Jan Honzicek, Jaromír Vinklárek Two series of heterobimetallic compounds were prepared from the starting complex [cis-L2PtCl2] containing aminophosphine ligand (L = 2,6-iPr2-C6H3-NHPPh2). They cover neutral Pt-Sn complexes [cis-L2PtX(SnCl3)] (X = Cl, SnCl3) and ionic... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Analyst, 2021, Advance Article DOI: 10.1039/D1AN00938A, PaperWei Zhang, Ioannis Karagiannidis, Eliane De Santana Van Vliet, Ruoxin Yao, Ellen J. Beswick, Anhong Zhou Raman spectra acquired from a single living cell were analyzed by a machine learning based algorithm and transformed into aggressiveness score, and further paired with gene expression data for correlation analysis. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growt...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 21 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks. Faricimab was generally well-tolerated, with no new safety signals identified. The studies each h...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Sarah K. Azzam1, Wael M. Osman2, Sungmun Lee1, Kinda Khalaf1, Ahsan H. Khandoker1, Wael Almahmeed3,4, Herbert F. Jelinek5 and Habiba S. Al Safar1,2* 1Biomedical Engineering Department, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 2Khalifa University Center of Biotechnology, Abu Dhabi, United Arab Emirates 3Institute of Cardiac Science, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates 4Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, United Arab Emirates 5Australian School of Advanced Medicine, Sydney and School of Community Health, Charles Sturt University, Ma...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
In this study, we found that TXNIP deficiency induces accelerated senescent phenotypes of mouse embryonic fibroblast (MEF) cells under high glucose condition and that the induction of cellular ROS or AKT activation is critical for cellular senescence. Our results also revealed that TXNIP inhibits AKT activity by a direct interaction, which is upregulated by high glucose and H2O2 treatment. In addition, TXNIP knockout mice exhibited an increase in glucose uptake and aging-associated phenotypes including a decrease in energy metabolism and induction of cellular senescence and aging-associated gene expression. We propose that...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Academies | Age-Related Macular Degeneration (AMD) | Alfalfa | Allergy & Immunology | Biotechnology | Blindness | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Endocrinology | Epidemiology | Eye Implants | Gene Therapy | Genetics | Heart | Hypermetropia (long sighted) | Infectious Diseases | International Medicine & Public Health | Internet | Japan Health | Lucentis | Men | Neurology | Opthalmology | Pharmaceuticals | Ranibizumab Injection | Science | Study | Switzerland Health | UK Health | USA Health | Vitamin A | WHO